Skip to main content
Top
Published in: Journal of the International AIDS Society 4/2010

Open Access 01-12-2010 | Poster presentation

Switching from tipranavir (TPV) 500/ritonavir (RTV) 200 mg to TPV 500/RTV 100 mg in treatment-experienced patients (pts) with HIV RNA <50 copies/mL

Authors: JL Casado, P Domingo, R Rubio, A Antela, MA Lopez-Ruz, A Castro, J Portilla, E Ribera, D Podzamczer, JA Oteo, J Galindo, S Otero, F Lozano, V Estrada, J Moltó, S Moreno

Published in: Journal of the International AIDS Society | Special Issue 4/2010

Login to get access

Excerpt

The administration of 200 mg of RTV to boost TPV plasma levels is associated with poor tolerance and toxicity. Some studies have shown that 100 mg of RTV could be enough to reach plasma levels of TPV that inhibit most HIV strains. This clinical trial was designed to show the efficacy and tolerability of switching to TPV 500/RTV 100 in patients with suppressed viremia receiving TPV 500/RTV 200. …
Metadata
Title
Switching from tipranavir (TPV) 500/ritonavir (RTV) 200 mg to TPV 500/RTV 100 mg in treatment-experienced patients (pts) with HIV RNA <50 copies/mL
Authors
JL Casado
P Domingo
R Rubio
A Antela
MA Lopez-Ruz
A Castro
J Portilla
E Ribera
D Podzamczer
JA Oteo
J Galindo
S Otero
F Lozano
V Estrada
J Moltó
S Moreno
Publication date
01-12-2010
Publisher
BioMed Central
DOI
https://doi.org/10.1186/1758-2652-13-S4-P49

Other articles of this Special Issue 4/2010

Journal of the International AIDS Society 4/2010 Go to the issue